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ABSTRACT: We reported previously the discovery of the
potent antimalarial 40-membered macrolide bastimolide A (1)
from the tropical marine cyanobacterium Okeania hirsute.
Continued investigation has led to the discovery of a new
analogue, bastimolide B (2), a 24-membered polyhydroxy
macrolide with a long aliphatic chain and unique terminal tert-
butyl group. Its complete structure was determined by a
combination of extensive spectroscopic methods and com-
parative analysis of its methanolysis products with those of bastimolide A. A methanolysis mechanism for bastimolide A is
proposed, and one unexpected isomerization product of the C2−C3 double bond, 2-(E)-bastimolide A (3), was obtained.
Bastimolide B (2) showed strong antimalarial activity against chloroquine-sensitive Plasmodium falciparum strain HB3. A
preliminary investigation of the structure−activity relationship based on six analogues revealed the importance of the double
bond as well as the 1,3-diol and 1,3,5-triol functionalities.
Marine cyanobacteria are exceptionally prolific producersof structurally diverse and biologically active secondary
metabolites.1,2 There is one approved anticancer agent that
owes its origin to a marine cyanobacterial metabolite and a
number of related agents in clinical trials,3 and while peptides
including lipopeptides are the dominant class of metabolites
from these organisms, there are also several unique
polyhydroxy macrolides with 36-membered rings (caylobolides
A4 and B5) or 40-membered rings (amantelides A and B6 and
nuiapolide7). Most of these latter agents have shown potent
cytotoxic or antichemotactic activities. Recently, we also
discovered an intriguing 40-membered-ring polyhydroxy
macrolide, named bastimolide A (1), and demonstrated its
potent and selective antimalarial activity against four multidrug-
resistant strains of Plasmodium falciparum.8 Due to the
considerable challenge of firm identification of the config-
urations for 1,n-diol (n ≥ 5) moieties,9 bastimolide A is the
only example for which the planar structure and absolute
configuration has been completely identified.8
As part of the Panama International Cooperative Biodiversity
Group (ICBG) to discover antiparasitic lead compounds from
marine microorganisms, further chemical investigation of the
new genus/species of tropical marine cyanobacterium Okeania
hirsuta (PAB-19MAY11-4) was undertaken for its antimalarial
constituents. This investigation has now resulted in the
isolation of bastimolide B (2), a 24-membered macrolide.
This new polyketide-derived compound is the first 24-
membered macrolide isolated from a marine cyanobacterium
and possesses a highly oxidized side chain and unique tert-butyl
group. Herein, we report its discovery, structure determination,
antimalarial activity, and the preliminary structure−activity
relationship.
A freeze-dried sample of the cyanobacterium O. hirsuta
collected from near the Isla Bastimentos Park, Panama, in 2011,
was repeatedly extracted with CH2Cl2/MeOH (2:1), and the
resulting extract was fractionated by silica gel vacuum liquid
chromatography (VLC) to produce nine subfractions (A−I).
Fraction I was further separated using RP SPE [starting with
20% MeOH in H2O to 100% MeOH, to produce four
fractions]. Fraction 2 (40% MeOH in H2O) was further
separated by RP HPLC to obtain compound 2 (1.8 mg).
Pure bastimolide B (2) was thus obtained as an optically
active white powder and gave by HRESITOFMS an [M + Na]+
peak at m/z 811.5907 (calcd for C44H84O11Na, 811.5906),
requiring three degrees of unsaturation. A strong IR absorption
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band at 1700 cm−1 suggested an ester group, and this was
supported by the presence of a carbonyl signal at δC 166.7 in
the 13C NMR spectrum (Table 1). The relatively shielded shift
of this ester carbonyl, together with the UV absorption
maximum at 214 nm, suggested α,β-unsaturation; this was
supported by HMBC and other 1H NMR analysis (Supporting
Information, Table S1). Furthermore, a methyl group (δH 1.77,
δC 25.4) was located by HMBC at the β-position to define a
trisubstituted α,β-unsaturated ester motif. Considering the
molecular formula and remainder of the NMR data, the
structure of 2 was thus suggested to contain a single ring.
The 1H NMR spectrum of bastimolide B (pyridine-d5)
showed a single olefinic proton (δH 5.83), nine protons on
oxygenated carbons at δH 3.47−4.59 along with one more
deshielded resonance at δH 5.63, and nine exchangeable
protons at δH 5.71−6.12. Additionally, there was an intense
9H singlet at δH 1.08 due to three isochronous methyl groups
comprising a tert-butyl moiety; one singlet methyl group (δH
1.77); and 52 methylene protons including 49 that were
significantly overlapped at δH 1.41−2.19. Between the 13C
NMR (Table 1) and HSQC spectra of 2, all 44 carbon
resonances were observable and included one carbonyl, two
quaternary carbons (including one olefinic carbon), 10
oxygenated methines (δC 66.3−79.3), 26 methylenes, and
four methyl groups (including one tert-butyl). These data taken
together with the co-occurrence of bastimolide A (1)8
suggested that compound 2 was a related polyhydroxy
macrolide.
The most obvious difference in the 1H NMR spectra
between bastimolides A and B was the relatively deshielded
chemical shift of H-23 (δH 5.63) in 2, instead of the relatively
shielded chemical shift of H-23 (δH 4.28) in 1. Correspond-
ingly, H-39 was relatively shielded in bastimolide B (δH 3.47 in
2 vs 5.09 in 1). Based on the above data, together with key
HMBC correlations between H-23 and the C-1 ester carbonyl
group, the location of lactone formation was established as
between C-1 and C-23 in 2 (versus C-1 and C-39 in 1).
Furthermore, detailed interpretation of 1D and 2D NMR
spectra (COSY, TOCSY, HSQC, and HMBC) allowed location
of one 1,3-diol system (C-9 and C-11), one 1,3,5-triol system
(C-19, C-21, and C-23), and six repeating 1,5-diol moieties
(Figure 1). The relative configurations of the 1,3-diol group (C-
9/C-11) and 1,3,5-triol system (C-19/C-21/C-23) were
identified as syn and anti/syn by Kishi’s Universal NMR
database10 and the equivalence or nonequivalence of the
intervening methylene protons.8,11 Finally, the Z-configured
double bond (C-2/C-3) was defined by a selective 1D NOE
experiment and the deshielded chemical shift of the C-44
methyl carbon at δC 25.4.
8
On the basis of the co-occurrence and shared biogenesis with
1, along with a careful comparison of 1H and 13C NMR data of
2 (Table 1) with those of 1, we propose the absolute
configuration of the two metabolites to be the same. To
confirm this assignment, we attempted to compare the
hydrolysis products of 1 and 2 and show their co-identities.
Unfortunately, bastimolide A (1) was unreactive to relatively
mild acidic (1, 3, and 4 M HCl) or basic conditions (saturated
solutions of LiOH, NaOH, or KOH) at different temperatures
(30−90 °C). As we have seen in other esters with adjacent
sterically bulky and hydrophobic tert-butyl groups, such as
palmyrolide A,12 they are highly resistant to hydrolytic
conditions. However, treatment of 1 with NaOMe in MeOH
and H2O quickly (<1 h) resulted in production of new
products by LCMS. Over a 10-day period of subjecting
bastimolide A (1) to these conditions, we monitored the
consecutive production of several products (Supporting
Information). Initially, two compounds (3 and 1a) with the
same molecular weights (m/z 788) as bastimolides A and B
were observed. Subsequently, three corresponding bastimolide
methyl esters (Supporting Information structures 1b, 1c, and
1d, m/z 820) were produced. Finally, three polar derivatives,
the seco acids of 1, 3, and 1a (Supporting Information
structures 1e, 1f, and 1g), dominated as the major products
with m/z values of 806. When any of the above bases were used
in the presence of MeOH, the same product profiles were
obtained in each case, and thus MeOH appears to play an
important role in this reaction (Scheme S2). Importantly, in all
cases, the C2−C3 double-bond isomerization product, 2-(E)-
bastimolide A (3) (Supporting Information, Scheme S1), was
produced from bastimolide A (1), and its structure was
determined by spectroscopic methods (Supporting Informa-
tion).
Fortunately, the more vigorous basic hydrolysis conditions
(50.0 μg of bastimolide B (2), 0.1 mL of NaOMe, 0.4 mL of
MeOH, 40 °C, 8 h) were able to affect ester hydrolysis. A
comparison of LCMS retention times and fragmentations for
the three main hydrolysis products (Supporting Information)
from bastimolide A (1) and bastimolide B (2) showed they
were identical. Hence, based on spectroscopic, chemical, and
biosynthetic considerations, we assign bastimolide B (2) to
possess the same absolute configuration as bastimolide A (1).
Although the absolute configuration of 1 was established by
X-ray crystallographic analysis, electronic circular dichroism
(ECD) chiroptical methods were also applied to compounds
1−3.13 First, the absolute configuration of the known 40-
membered-ring polyhydroxy macrolide bastimolide A (1) was
verified by comparing its computed ECD spectrum with the
experimental result. A total of 729 lowest energy conformers of
1, with relative energies extending from 0 to 10.0 kcal/mol,
were searched using the MMFF94S force field and used for
structural optimizations and ECD computations. Boltzmann
statistics were performed for ECD simulations with a standard
deviation of σ 0.4 eV. The predicted ECD curve matched well
with the experimental result of bastimolide A (1) (Figure S74),
suggesting the accuracy and applicability of the ECD method to
these macrolides. In the course of these preliminary studies, it
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was observed that the preferential conformations of 1 contained
several hydrogen bonds, resulting in a relatively rigid structure
for 1 (Figure S76).
For 3, the experimental ECD spectrum was almost opposite
to that of the calculated spectrum and implied that the 39R-
epimer of 1 was also a structural possibility. Thus, conforma-
Table 1. NMR Spectroscopic Data (1H 800 MHz, 13C 200 MHz, Pyridine-d5) for Bastimolide B (2)
position δC, type
a δH (J in Hz) HMBC
a TOCSY
1 166.7, C
2 117.5, CH 5.83, s 1, 3, 4, 44 44
3 160.7, C
4 33.7, CH2 3.14, dd (8, 4); 2.41, m 2, 3, 5, 6, 44 5
5 28.9, CH2 1.52, m 3, 4, 6, 7 4, 6
6 30.2, CH2 1.46, m 4, 5, 7 4, 5, 7, 9
1.42, m
7 26.1, CH2 1.65, m
b
1.60, mb
8 39.3, CH2 1.65−1.98, mb
9 71.7, CH 4.23, br s 5, 6, 7, 10, 9-OH
10 44.5, CH2 2.04, m
b 9, 11
1.96, mb
11 71.7, CH 4.32, brs 9, 10, 11-OH
12 39.2, CH2 1.65−1.98, mb
13 22.4, CH2 1.77, m
b
14 39.1, CH2 1.65−1.98, mb
15 71.4, CH 3.96, mb 15-OH
16 39.1, CH2 1.65−1.98, mb
17 21.5, CH2 1.77, m
b
18 39.1, CH2 1.65−1.98, mb
19 68.3, CH 4.51, brs 20, 21, 22, 19-OH
20 44.9, CH2 2.01, m 19, 21, 22 19, 21, 22, 23, 19-OH, 21-OH
21 66.3, CH 4.59, br s 19, 20, 22, 23, 21-OH
22 44.0, CH2 2.34, ddd (8, 4, 4); 2.05, m
b 21, 23, 24 19, 20, 21, 23, 24, 21-OH
23 71.6, CH 5.63, m 1, 21, 24, 25 21, 22, 24
24 35.9, CH2 1.87, m
b
25 22.7, CH2 1.70, m
b
26 37.4, CH2 1.65−1.98, mb
27 70.7, CH 4.07, mb 27-OH
28 38.3, CH2 1.65−1.98, mb
29 23.4, CH2 1.77, m
b
30 38.8, CH2 1.65−1.98, mb
31 71.6, CH 3.94, mb 31-OH
32 38.9, CH2 1.65−1.98, mb
33 23.4, CH2 1.77, m
b
34 39.0, CH2 1.65−1.98, mb
35 71.2, CH 3.88, brs 37, 35-OH
36 37.6, CH2 1.65−1.98, mb
37 24.7, CH2 2.16, m
b
1.94, mb
38 32.7, CH2 1.62, m
39 79.3, CH 3.47, m 38, 40, 41−43 37, 38, 39-OH
40 35.8, C
41−43 26.8, CH3 1.08, s 39, 40
44 25.4, CH3 1.77, s 2, 3, 4
9-OH 6.04, br d (2.4)b 8, 9, 11
11-OH 6.12, br d (3.2) 10, 11
15-OH 5.76, br d (4.8) 15
19-OH 5.87, d (4.0) 19, 20
21-OH 6.06, d (4.8) 21, 22
27-OH 5.74b 27
31-OH 5.72 31
35-OH 5.74b 35
39-OH 5.71, d (5.6) 39
aHMBC correlations, optimized for 8 Hz, are from proton(s) stated to the indicated carbon. bSignal overlapped with other signals.
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tional searches were performed using the MMFF94S force field
for (2E)-bastimolide A (3a) as well as (39R)-bastimolide A
(3b). All geometries (746 lowest energy conformers for 3a and
1239 for 3b, respectively) with relative energies from 0 to 10.0
kcal/mol were used in optimizations at the B3LYP/6-31G(d)
level using the Gaussian09 package. The B3LYP/6-31G(d)-
optimized conformers (124 lowest energy conformers for 3a
and 167 for 3b) with relative energy from 0 to 2.0 kcal/mol
were then reoptimized at the B3LYP/6-311+G(d) level.
Boltzmann statistics were performed for ECD simulations
with a standard deviation (σ) of 0.2 eV. The predicted ECD for
3a matched better with the experimental result of 3 (Figure
S77), suggesting that 3 was indeed the 2E-isomer of
bastimolide A (1). Interestingly, the ECD curve of 3 was
principally affected by the double-bond configuration between
C-2 and C-3 rather than the C-39 stereogenic carbon,
suggesting a new application of ECD calculations to small-
molecule molecular structures. Further, our calculations
suggested that compound 3a possesses a rigid structure due
to the presence of hydrogen bonds, whereas in 3b the change in
direction of the C-1 carbonyl was predicted to disrupt this
hydrogen bond network and increase structural flexibility
(Figure S76). Finally, attempts to confirm the absolute
configuration of bastimolide B (2) by the ECD method were
unsuccessful. At the present time, the presence of multiple
different hydrogen bonds among the side chain hydroxy groups
in 2 prevented this type of computational approach.
Bastimolide A (1), bastimolide B (2), and 2-(E)-bastimolide
A (3), together with three previously prepared acetonide
derivatives of bastimolide A (1i−1k),8 were evaluated for their
antimalarial activities against chloroquine-sensitive Plasmodium
falciparum strain HB3. The natural products (1 and 2) and
their derivatives had widely varying antimalarial effects (Table
2). While the natural products 1 and 2 showed pronounced
antimalarial activity with EC50 values of 2.6 ± 0.2 and 5.7 ± 0.7
μM, respectively, it was 2-(E)-bastimolide A (3) that showed
the greatest potency, with an EC50 value of 1.4 ± 0.5 μM. The
acetonide derivative of the C-21/C-23 hydroxy groups (1i) had
an 8-fold decrease in potency, whereas the C-9/C-11 acetonide
(1j) had nearly the same potency as bastimolide A (1),
indicating that the 9-OH/11-OH groups have little effect on
the antimalarial activity.
In summary, we report here the isolation and structure
elucidation of bastimolide B (2), a new 24-membered
polyhydroxy macrolide with a unique terminal tert-butyl
group. The bastimolides show considerable antimalarial activity
against chloroquine-sensitive P. falciparum strain HB3 and
represent an intriguing new class of antimalarial agent. The
discovery of this new polyhydroxy macrolide further suggests
that the cyanobacterial genus Okeania should be a significant
resource of structurally interesting molecules in the future.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured with a JASCO P-2000 polarimeter. UV/visual-light spectra
were recorded on a Beckman Coulter DU 880 spectrophotometer.
ECD spectra were recorded in MeOH using a JASCO J-810
spectropolarimeter. IR spectra were recorded using a Thermo Electron
Corporation Nicolet IR 100 FT-IR and KBr plates. NMR spectra were
recorded on Varian 500 MHz or vs800 MHz spectrometers in
methanol-d4 or pyridine-d5. Chemical shifts δ are reported using
tetramethylsilane as an internal standard. High-resolution mass spectra
were carried out on an Agilent 6230 TOF-MS under positive ion ESI-
TOF-MS conditions in the University of California, San Diego
(UCSD), Small Molecule MS Facility. All solvents were purchased as
HPLC grade.
Sampling and Taxonomic Characterization. The cyanobacte-
rium was identified as Okeania hirsuta.8
Extraction and Isolation. The sample was extracted with 2:1
CH2Cl2/MeOH and fractionated to obtain 76.8 mg of bastimolide A
as previously described.8 Fraction 2 (40% MeOH in H2O) from the
RP SPE fractionation step was further separated by RP HPLC (Synergi
10 μm C18, 80 Å, 250 × 10 mm, 70% MeOH/H2O at 3 mL/min,
detection at 210, 230, and 250 nm) to obtain pure compound 2 (1.8
mg) at tR 34.0 min.
Bastimolide B (2): white powder; [α]25D −11.3 (c 0.75, MeOH);
UV (MeOH) λmax (log ε) 214 (4.24) nm; ECD (0.63 mM, MeOH)
λmax (Δε) 222 (−5.12); IR (KBr) νmax 3399, 2931, 1700, 1383, 1114
cm−1; 1H NMR (pyridine-d5, 800 MHz) and
13C NMR (pyridine-d5,
200 MHz), see Table 1; 1H NMR (CD3OD, 500 MHz) 5.70 (H-2,
1H, s), 5.06 (H-23, 1H, m), 3.90 (H-21, 1H, m), 3.85 (H-19, 1H, m),
3.78 (1H, m), 3.73 (1H, m), 3.62 (1H, m), 3.54 (3H, overlapped),
3.12 (H-39, 1H, d, 10.5 Hz), 2.88 (H-4, 1H, m), 2.40 (H-4, 1H, m),
1.91 (H-44, 3H, s, −CH3), 1.83 (H-22, 1H, m), 1.72 (H-22, 1H, m),
1.65 (H-10, 1H, m), 1.56 (H-20, 2H, m), 1.51 (H-10, 1H, m), 1.29−
1.73 (44H, overlapped), 0.89 (H-41, 42, 43, 9H, s, −3CH3); 13C NMR
(CD3OD, 125 MHz) 167.8 (C-1), 117.1 (C-2), 162.6 (C-3), 80.5 (C-
39), 71.8 (C-23), 68.8 (C-19), 66.7 (C-21), 71.5 (C-9), 71.1 (C-11),
70.8 (C-27), [72.4, 72.4, 72.2, (C-15, 31, 35)], 44.3 (C-10), 44.1 (C-
20), 43.5 (C-22), [38.5, 38.4, 38.4, 38.4, 38.4, 38.3, 38.2, 38.1, 37.9,
37.0, 36.9, (C-8, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36)], 35.9 (C-24),
35.8 (C-40), 34.2 (C-4), 32.3 (C-38), 30.6 (C-6), 29.3 (C-5), 26.4 (C-
41, 42, 43), 26.0 (C-7), 25.4 (C-44), [24.4, 23.0, 23.0, 22.5, 21.9, 21.4,
(C-13, 17, 25, 29, 33, 37)]; ESITOFMS m/z 811.62 [M + Na]+;
ESITOFMS m/z 787.54 [M − H]−; HRESITOFMS m/z 811.5907
[M + Na]+ (calcd for C44H84O11Na, 811.5906).
Preparation of the Isomerization Product 2-(E)-Bastimolide
A (3). To a stirred solution of 1 (5.0 mg) in MeOH (1.0 mL) was
added 0.5 mL of NaOMe in MeOH. The reaction mixture was stirred
at room temparature for 8 h and then quenched with distilled H2O.
The mixture was extracted with EtOAc, and the organic extract was
evaporated to dryness. The resulting residue was purified by RP HPLC
(Synergic 10 μm C18, 80 Å, 250 × 10 mm, 70% MeOH/H2O at 3
mL/min, detection at 210, 230, and 250 nm) to obtain pure
compound 3 (2.4 mg).
2-(E)-Bastimolide A (3): white powder; [α]25D −10 (c 0.2, MeOH);
UV (MeOH) λmax (log ε) 214 (3.86) nm; ECD (0.63 mM, MeOH)
Figure 1. Key NMR-based connections for bastimolide B (2).
Table 2. Antimalarial Activity of Compounds 1−3 and 1i−1k
against Chloroquine-Sensitive P. falciparum Strain HB3
compound IC50 (μM)
bastimolide A (1) 2.6 ± 0.2
bastimolide B (2) 5.7 ± 0.7
2-(E)-bastimolide A (3) 1.4 ± 0.5
acetonide A (1i) 20 ± 3
acetonide B (1j) 2.3 ± 0.2
acetonide C (1k) 9.7 ± 1.7
chloroquine 0.063 ± 0.025
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λmax (Δε) 225 (5.82); IR (KBr) νmax 3379, 2933, 2861, 2360, 2338,
1650, 1457, 1324, 1223, and 672 cm−1; 1H NMR (pyridine-d5, 500
MHz) 6.29 (−OH, br s), 6.24 (−OH, br s), 6.20 (−OH, br s), 6.16
(−OH, br s), 6.03 (−OH, d, 3.5), 5.97 (1H, s), 5.80−5.75 (4OH,
overlapped), 5.12 (1H, t, 6.0), 4.75 (1H, br s), 4.46 (1H, br s), 4.26
(2H, overlapped), 4.17 (1H, br s), 3.95 (3H, overlapped), 3.85 (1H,
s), 2.29 (3H, s), 2.15−1.58 (47H, overlapped), 1.50 (1H, m), 1.41
(2H, m), 1.30 (2H, m), 0.96 (9H, s); 13C NMR (pyridine-d5, 125
MHz) 167.3 (C-1), 160.7 (C-3), 116.5 (C-2), 80.1 (C-39), 72.1 (C-
11), 71.9 (C-9), [71.5, 71.4, 71.3, 71.3, 71.2 (C-15, 23, 27, 31, 35)],
69.5 (C-21), 68.6 (C-19), [45.5, 45.5, 45.0 (C-10, 20, 22)], 41.3 (C-4),
[39.4, 39.3, 39.1, 39.0, 39.0, 39.0, 39.0, 39.0, 38.9, 38.7, 38.7, 38.7 (C-8,
12, 14, 16, 18, 24, 26, 28, 30, 32, 34, 36)], 35.1 (C-40), 30.7 (C-38),
30.0 (C-6), 28.0 (C-5), 26.5 (C-41, 42, 43), 26.1 (C-7), [24.0, 23.3,
23.3, 22.9, 22.7, 22.6 (C-13, 17, 25, 29, 33, 37)], 19.2 (C-44); 1H
NMR (CD3OD, 500 MHz) 5.70 (1H, s), 4.77 (1H, d, 10.5 Hz), 4.00
(1H, t, 5.5 Hz), 3.83 (1H, br s), 3.76 (3H, overlapped), 3.59−3.47
(4H, overlapped), 2.20 (2H, t, 7.0 Hz), 2.15 (3H, s), 1.64−1.28 (50H,
overlapped), 0.91 (9H, s); 13C NMR (CD3OD, 125 MHz): 168.6 (C-
1), 161.8 (C-3), 116.7 (C-2), 81.1 (C-39), 72.3 (C-11), 72.3 (C-9),
[72.1, 72.0, 71.5, 71.5, 70.8 (C-15, 23, 27, 31, 35)], 69.0 (C-21), 68.5
(C-19), [45.4, 45.1, 44.8 (C-10, 20, 22)], 41.8 (C-4), [38.7, 38.5, 38.4,
38.4, 38.3, 38.3, 38.3, 38.2, 38.2, 38.0, 38.0, 38.0 (C-8, 12, 14, 16, 18,
24, 26, 28, 30, 32, 34, 36)], 35.5 (C-40), 30.9 (C-38), 30.2 (C-6), 28.5
(C-5), 26.4 (C-41, 42, 43), 26.2 (C-7), [23.7, 23.0, 22.9, 22.5, 22.4,
22.3 (C-13, 17, 25, 29, 33, 37)], 19.0 (C-44); HRESITOFMS m/z
789.6078 [M + H]+ (calcd for C44H85O11, 789.6086).
Computational Section. Quantum theory is well developed and
used in energy calculations, analytic gradients, and true analytic
frequencies study. The ECD spectra of compounds 1 and 3 were
calculated by time-dependent density functional theory and compared
with experimental spectra. Before ECD calculations, all the conformers
were optimized by the Gaussian09 program to ensure that all the
conformers were the optimum structures with low energetics.14 After
the calculations of ECD for each conformation, Boltzmann statistics
were used to simulate their corresponding values, respectively.
Antimalarial Activity. Antimalarial activities of all compounds
were assayed following the procedures previously reported, which used
Pico-Green to assess parasite growth inhibition by drugs, and
chloroquine was used as positive control.15
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